Enovis (ENOV) Income from Discontinued Operations (2016 - 2026)
Enovis' (ENOV) quarterly Income from Discontinued Operations came in at -$39000.0 in Q2 2026, up 68.8% year-over-year from -$23104.3 in Q2 2025, and up 97.64% quarter-over-quarter from -$1.7 million in Q4 2025.
Analysis
Enovis (ENOV) Income from Discontinued Operations (2016 - 2026) Analysis & Trends
Enovis (ENOV) has reported Income from Discontinued Operations for 11 consecutive years, with -$39000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income from Discontinued Operations rose 68.8% year-over-year to -$39000.0 in Q2 2026; TTM through Jul 2026 was -$1.7 million, a 170.58% decrease from a year earlier, with the FY2025 full-year figure at -$1.9 million, down 173.39% from the prior year.
- Income from Discontinued Operations was -$39000.0 for Q2 2026 at Enovis, up from -$1.7 million in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at $54.4 million in Q2 2022 and troughed at -$43.7 million in Q3 2022.
- A 5-year average of $3.0 million and a median of -$39500.0 in 2025 frame the typical range for Income from Discontinued Operations.
- Across the five-year window, Income from Discontinued Operations soared 3450.0% in 2024 and sank 487.56% in 2025, its largest moves.
- Over 5 years, Income from Discontinued Operations stood at $16.3 million in 2022, then slumped by 99.93% to $12000.0 in 2023, then soared by 3450.0% to $426000.0 in 2024, then slumped by 487.56% to -$1.7 million in 2025, then jumped by 97.64% to -$39000.0 in 2026.
- The last three Income from Discontinued Operations figures came in at -$39000.0 (Q2 2026), -$1.7 million (Q4 2025), and -$40000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.94 Bn | 176.34 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.82 Bn | 122.60 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.97 Bn | 109.15 Bn | 6.34 Bn | - |
| 4 | Stryker | 105.64 Bn | 102.16 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 65.05 Bn | 64.51 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.87 Bn | 45.62 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.26 Bn | 31.80 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | - |
| 9 | Steris | 20.80 Bn | 20.32 Bn | 684.20 Mn | - |
| 10 | Enovis | 1.08 Bn | 1.06 Bn | 359.25 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 3, 2026 | -39,000.00 |
| Dec 31, 2025 | -1.65 Mn |
| Oct 3, 2025 | -40,000.00 |
| Jul 4, 2025 | -93,000.00 |
| Apr 4, 2025 | -125,000.00 |
| Dec 31, 2024 | 426,000.00 |
| Sep 27, 2024 | 2.24 Mn |
| Jun 28, 2024 | -68,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 29, 2023 | 16.61 Mn |
| Jun 30, 2023 | 4.80 Mn |
| Mar 31, 2023 | -312,000.00 |
| Dec 31, 2022 | 16.27 Mn |
| Sep 30, 2022 | -527,000.00 |
| Jul 1, 2022 | -43.67 Mn |
| Apr 1, 2022 | 54.36 Mn |
| Dec 31, 2021 | 14.17 Mn |
| Oct 1, 2021 | 40.44 Mn |
| Jul 2, 2021 | 71.83 Mn |
| Apr 2, 2021 | 52.09 Mn |